Literature DB >> 21645027

Periodontopathogen- and host-derived immune response in acute coronary syndrome.

H Alfakry1, S Paju, J Sinisalo, M S Nieminen, V Valtonen, P Saikku, M Leinonen, P J Pussinen.   

Abstract

Owing to molecular mimicry, periodontal pathogen carriage may result in a systemic cross-reactive immune response with the host. The analyses were performed to investigate if serum antibody levels to human heat shock protein 60 (HSP60) are associated with the antibody levels and salivary carriage of two periodontal pathogens, Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis, as well as with the dental status in patients with acute coronary syndrome (ACS). ACS patients (n = 141) were monitored at baseline when entering to hospital, and after 1 week, 3 months and 1 year. Periodontal status was recorded by dental radiographs, and A. actinomycetemcomitans and P. gingivalis were detected by PCR from saliva at baseline. Serum IgG and IgA antibody levels were determined at all time points. All antibody levels remained quite stable during the follow-up. Serum IgG-class antibody levels to A. actinomycetemcomitans and HSP60 had a strong positive correlation with each other at all time points (r∼0.4, P < 0.05). Mean serum IgG antibody levels to HSP60 were significantly higher in the A. actinomycetemcomitans IgG- and IgA-seropositive than in the seronegative patients, but did not differ between the pathogen carriers compared to the non-carriers. HSP60 antibody levels did not differ significantly between the edentulous, non-periodontitis and periodontitis patients. Despite the observed cross-reactivity in the systemic IgG-class antibody response to HSP60 and A. actinomycetemcomitans, the pathogen carriage in saliva or the periodontal status did not affect the HSP60 antibody levels in ACS patients.
© 2011 The Authors. Scandinavian Journal of Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645027     DOI: 10.1111/j.1365-3083.2011.02584.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Characterization of a natural mouse monoclonal antibody recognizing epitopes shared by oxidized low-density lipoprotein and chaperonin 60 of Aggregatibacter actinomycetemcomitans.

Authors:  Chunguang Wang; Jari Kankaanpää; Outi Kummu; S Pauliina Turunen; Ramin Akhi; Ulrich Bergmann; Pirkko Pussinen; Anne M Remes; Sohvi Hörkkö
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

2.  Microbial carriage state of peripheral blood dendritic cells (DCs) in chronic periodontitis influences DC differentiation, atherogenic potential.

Authors:  Julio Carrion; Elizabeth Scisci; Brodie Miles; Gregory J Sabino; Amir E Zeituni; Ying Gu; Adam Bear; Caroline A Genco; David L Brown; Christopher W Cutler
Journal:  J Immunol       Date:  2012-08-13       Impact factor: 5.422

3.  Inverse Association of Plasma IgG Antibody to Aggregatibacter actinomycetemcomitans and High C-Reactive Protein Levels in Patients with Metabolic Syndrome and Periodontitis.

Authors:  Supanee Thanakun; Suchaya Pornprasertsuk-Damrongsri; Misa Gokyu; Hiroaki Kobayashi; Yuichi Izumi
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 4.  Oral Dysbiosis and Autoimmunity: From Local Periodontal Responses to an Imbalanced Systemic Immunity. A Review.

Authors:  Lina J Suárez; Hernan Garzón; Silie Arboleda; Adriana Rodríguez
Journal:  Front Immunol       Date:  2020-12-08       Impact factor: 7.561

5.  Early Biomarkers of Periodontitis: New Challenges for a Personalized Medicine Approach.

Authors:  Gaetano Isola
Journal:  Int J Environ Res Public Health       Date:  2021-12-27       Impact factor: 3.390

6.  Association among serum and salivary A. actinomycetemcomitans specific immunoglobulin antibodies and periodontitis.

Authors:  Gaetano Isola; Alessandro Polizzi; Romeo Patini; Sebastiano Ferlito; Angela Alibrandi; Giuseppe Palazzo
Journal:  BMC Oral Health       Date:  2020-10-15       Impact factor: 2.757

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.